{
    "name": "ertugliflozin",
    "comment": "Rx",
    "other_names": [
        "Steglatro"
    ],
    "classes": [
        "Antidiabetics",
        "SGLT2 Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/steglatro-ertugliflozin-1000188",
    "pregnancy": {
        "common": [
            "Based on animal data showing adverse renal effects, not recommended during the second and third trimesters of pregnancy",
            "Data are limited in pregnant women and are not sufficient to determine a drug-associated risk of adverse developmental outcomes; there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal studies, adverse renal changes were observed in rats when ertugliflozin was administered during a period of renal development corresponding to the late second and third trimesters of human pregnancy; doses ~13 times the maximum clinical dose caused renal pelvic and tubule dilatations and renal mineralization that were not fully reversible",
                    "There was no evidence of fetal harm in rats or rabbits at exposures of ertugliflozin ~300 times higher than the maximal clinical dose of 15 mg/day when administered during organogenesis"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Not recommended while breastfeeding",
            "Unknown if distributed in human breast milk",
            "Since human kidney maturation occurs in utero and during the first 2 years of life when lactational exposure may occur, there may be risk to the developing human kidney",
            "Because of the potential for serious adverse reactions in a breastfed infant, advise women that ertugliflozin is not recommended while breastfeeding"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to ertugliflozin or any excipient; reactions such as angioedema have occurred ",
                "Patients on dialysis"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Causes intravascular volume contraction; symptomatic hypotension may occur after initiating, particularly in patients with renal impairment, with low systolic blood pressure, on diuretics, or who are elderly; before initiating treatment in patients with one or more of risk factors, assess volume status and renal function",
                "Renal impairment may occur owing to intravascular volume contraction; before initiating, consider factors that may predispose patients to acute kidney injury, including hypovolemia, chronic renal insufficiency, CHF, and concomitant medications (eg, diuretics, ACE inhibitors, ARBs, NSAIDs); consider temporarily discontinuing ertugliflozin in any setting of reduced oral intake or fluid loss; monitor for signs and symptoms of acute kidney injury, and, if evident, discontinue drug promptly and institute treatment",
                "Genital mycotic infections may occur; patients with history of genital mycotic infections and uncircumcised males are more susceptible",
                "Serious urinary tract infections, including urosepsis and pyelonephritis, requiring hospitalization reported in patients receiving SGLT2 inhibitors",
                "Increases risk of urinary tract infections (UTIs), including life-threatening urosepsis and pyelonephritis that started as UTIs",
                "Necrotizing fasciitis of the perineum (Fournier gangrene) reported with SGLT2 inhibitors; signs and symptoms include tenderness, redness, or swelling of the genitals or the area from the genitals back to the rectum, and have a fever above 100.4°F or a general feeling of being unwell; if suspected, discontinue SGLT2 inhibitor and start treatment immediately with broad-spectrum antibiotics and surgical debridement if necessary",
                "Dose-related increases in LDL-C reported",
                "No conclusive evidence of macrovascular risk reduction with empagliflozin or any other antidiabetic agent"
            ],
            "specific": [
                {
                    "type": "Lower limb amputations",
                    "description": [
                        "An increased risk for lower limb amputation (primarily of the toe) has been observed in clinical studies with another SGLT2 inhibitor; before initiating, consider factors that may predispose patient to increased risk of amputations (eg, history of prior amputation, peripheral vascular disease, neuropathy, diabetic foot ulcers)",
                        "Counsel patients about importance of routine preventative foot care; monitor patients receiving drug for signs and symptoms of infection (including osteomyelitis), new pain or tenderness, sores or ulcers involving the lower limbs, and discontinue therapy if these complications occur"
                    ]
                },
                {
                    "type": "Ketoacidosis",
                    "description": [
                        "Not indicated for patients with type 1 diabetes mellitus (T1DM); in placebo-controlled trials, risk of ketoacidosis was increased in patients with T1DM who received SGLT2 inhibitors",
                        "Risk of ketoacidosis may be greater with higher doses ",
                        "Before initiating therapy, consider factors in patient history that may predispose to ketoacidosis, including pancreatic insulin deficiency from any cause, caloric restriction, and alcohol abuse",
                        "Consider temporarily discontinuing therapy for at least 3 days for patients who undergo scheduled surgery",
                        "Consider monitoring for ketoacidosis and temporarily discontinuing therapy in other clinical situations known to predispose to ketoacidosis (eg, prolonged fasting due to acute illness or post-surgery); ensure risk factors for ketoacidosis are resolved prior to restarting therapy",
                        "Restart once the patient’s oral intake is back to baseline and any other risk factors for ketoacidosis (blood acid buildup) are resolved"
                    ]
                },
                {
                    "type": "Drug interactions overview ",
                    "description": [
                        "Hypoglycemia risk increased with insulin and insulin secretagogues (eg, sulfonylureas); a lower dose of insulin or insulin secretagogue may be required"
                    ]
                },
                {
                    "type": "Laboratory testing",
                    "description": [
                        "Urine glucose tests is not recommended in patients taking SGLT2 inhibitors, as SGLT2 inhibitors, increase urinary glucose excretion and lead to positive urine glucose tests; use alternative methods to monitor glycemic control",
                        "1,5-AG assay is not recommended, as measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors; use alternative methods to monitor glycemic control"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpropamide",
            "description": {
                "common": "ertugliflozin, chlorpropamide.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glimepiride",
            "description": {
                "common": "ertugliflozin, glimepiride.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glipizide",
            "description": {
                "common": "ertugliflozin, glipizide.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glyburide",
            "description": {
                "common": "ertugliflozin, glyburide.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "ifosfamide, ertugliflozin.\nEither increases toxicity of the other by nephrotoxicity and/or ototoxicity. Use Caution/Monitor. Monitor renal function in patients with severe renal impairment, severe intestinal inflammation, or prolonged use >2 gm/day."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin aspart",
            "description": {
                "common": "ertugliflozin, insulin aspart.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin aspart protamine/insulin aspart",
            "description": {
                "common": "ertugliflozin, insulin aspart protamine/insulin aspart.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec",
            "description": {
                "common": "ertugliflozin, insulin degludec.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin detemir",
            "description": {
                "common": "ertugliflozin, insulin detemir.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glargine",
            "description": {
                "common": "ertugliflozin, insulin glargine.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glulisine",
            "description": {
                "common": "ertugliflozin, insulin glulisine.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin inhaled",
            "description": {
                "common": "ertugliflozin, insulin inhaled.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin isophane human/insulin regular human",
            "description": {
                "common": "ertugliflozin, insulin isophane human/insulin regular human.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin lispro",
            "description": {
                "common": "ertugliflozin, insulin lispro.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin lispro protamine/insulin lispro",
            "description": {
                "common": "ertugliflozin, insulin lispro protamine/insulin lispro.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin NPH",
            "description": {
                "common": "ertugliflozin, insulin NPH.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin regular human",
            "description": {
                "common": "ertugliflozin, insulin regular human.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lithium",
            "description": {
                "common": "ertugliflozin decreases levels of lithium by Other (see comment). Use Caution/Monitor. \nComment: Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations; monitor serum lithium concentration more frequently during therapy initiation and dosage changes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lonapegsomatropin",
            "description": {
                "common": "lonapegsomatropin decreases effects of ertugliflozin by Other (see comment). Use Caution/Monitor. \nComment: Closely monitor blood glucose when treated with antidiabetic agents. Lonapegsomatropin may decrease insulin sensitivity, particularly at higher doses. Patients with diabetes mellitus may require adjustment of their doses of insulin and/or other antihyperglycemic agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nateglinide",
            "description": {
                "common": "ertugliflozin, nateglinide.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "repaglinide",
            "description": {
                "common": "ertugliflozin, repaglinide.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "somapacitan",
            "description": {
                "common": "somapacitan decreases effects of ertugliflozin by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Growth hormone products may decrease insulin sensitivity, particularly at higher doses. Antidiabetic agents may require dose adjustment after initiating somapacitan. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolazamide",
            "description": {
                "common": "ertugliflozin, tolazamide.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolbutamide",
            "description": {
                "common": "ertugliflozin, tolbutamide.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Female genital mycotic infections",
            "percent": "9.1-12.2"
        },
        {
            "name": "Volume depletion adverse effects",
            "percent": "1.9-4.4"
        },
        {
            "name": "Male genital mycotic infections",
            "percent": "3.7-4.2"
        },
        {
            "name": "Urinary tract infections",
            "percent": "4-4.1"
        },
        {
            "name": "Headache",
            "percent": "2.9-3.5"
        },
        {
            "name": "Vaginal pruritus",
            "percent": "2.4-2.8"
        },
        {
            "name": "Increased urination",
            "percent": "2.4-2.7"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "2-2.5"
        },
        {
            "name": "Back pain",
            "percent": "1.7-2.5"
        },
        {
            "name": "Renal adverse effects",
            "percent": "1.3-2.5"
        },
        {
            "name": "Weight decreased",
            "percent": "1.2-2.4"
        },
        {
            "name": "Thirst",
            "percent": "1.4-2.7"
        },
        {
            "name": "Adverse Effects",
            "percent": null
        },
        {
            "name": "Necrotizing fasciitis of the perineum",
            "percent": null
        },
        {
            "name": "Fournier",
            "percent": null
        },
        {
            "name": "s Gangrene",
            "percent": null
        },
        {
            "name": "Angioedema",
            "percent": null
        }
    ]
}